EGFR and lung carcinoma: PF0677775 is another oral inhibitor of EGFR T790M with 26-fold increased selectivity of mutant versus wild-type EGFR. It is currently under evaluation in a phase I/II study in patients with advanced EGFR mutation-positive lung cancer (del19 or L858R, T790M positive and negative) (NCT02349633) and early results have demonstrated activity and tolerability (54).